Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis
File version
Author(s)
McCartney, Lara
Goldschlager, Romi
Kisely, Steve
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Background: Although clozapine is the 'gold standard' for treatmentrefractory schizophrenia, meta-analyses of clozapine for this condition are lacking. Aims: We conducted a systematic review and meta-analysis of clozapine treatment for people with treatment-refractory schizophrenia. Method: We searched the Cochrane Schizophrenia Group's trial register, PubMed and EMBASE and hand-searched key papers for randomised controlled trials of clozapine for treatment-refractory schizophrenia. Results: Twenty-one papers with 25 comparisons were included. The number needed to treat was 9. Clozapine was superior for positive symptoms in both the short and long term. In the short term only clozapine was superior for total and negative symptoms, with higher response rates. Both funding source and dosage affected results. Higher baseline psychosis scores predicted better outcomes for clozapine in a meta-regression. Conclusions: Clozapine is superior for treatment-refractory disorder but if there is no response by 6 months medications with lower adverse reactions should be considered. Declaration of interest None.
Journal Title
British Journal of Psychiatry
Conference Title
Book Title
Edition
Volume
209
Issue
5
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Biomedical and clinical sciences
Psychology
Science & Technology
Life Sciences & Biomedicine
Psychiatry
TREATMENT-RESISTANT SCHIZOPHRENIA
CHILDHOOD-ONSET SCHIZOPHRENIA
Persistent link to this record
Citation
Siskind, D; McCartney, L; Goldschlager, R; Kisely, S, Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis, British Journal of Psychiatry, 2016, 209 (5), pp. 385-392